Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 30, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of

...

Yesterday, Schering-Plough Corp. (SGP) and Johnson & Johnson (JNJ) announced the approval of their drug Simponi (golimumab) in the European Union for the treatment of rheumatoid arthritis and other immune system disorders. The drug was approved by the U.S. Food and Drug Administration (FDA) in April 2009.   As a reminder, Schering acquired co-development rights to Simponi in the third quarter of 2005 from Johnson & Johnson’s biotech arm, Centocor Inc., which had developed and discovered the drug. Johnson & Johnson enjoys exclusive marketing rights of Simponi in the U.S., while Schering-Plough holds marketing rights outside the U.S.  excluding Japan, Indonesia and Taiwan where the drug will be co-marketed with other vendors subsequent to regulatory approvals.   Simponi, a next-generation, fully human, anti-tumor necrosis factor (TNF), received European approval as a once-a-month treatment for rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spondylitis (AS), which is a ...

Yesterday, Merck & Co. (MRK) announced that it is seeking approval from the European Union (EU) for its $41.1 billion acquisition of Schering-Plough Corp. (SGP). The regulatory authorities in the EU are expected to pass a verdict on the matter by Oct. 23. Merck filed for approval of the merger in the EU after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to Sanofi-Aventis (SNY) for a cash consideration of $4 billion ( US ). As a reminder, Merial was founded in 1997. It was a 50/50 joint venture between Merck and Sanofi-Aventis and is now a wholly owned subsidiary of the latter. In 2008, Merial was ranked third in the animal health market, with a market share estimated at 13.8% and sales of $2.7 billion just behind Schering’s animal health business, which registered sales ...

Yesterday, Schering-Plough Corp. (SGP) revealed that the European Medicines Agency (EMA) will review its candidate for maintenance treatment of asthma in patients 12 years and above and an oral contraceptive for marketing in Europe. While the fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years and above is currently under review by the U.S. Food and Drug Administration (FDA), the filing for FDA approval of the contraceptive is expected in 2010. The oral contraceptive is a combination of a natural estrogen (which is identical to the estrogen produced by a woman's body) and a selective progestin. The drug was licensed from Merck KGaA. Schering is seeking marketing approval in Europe for the combination to prevent pregnancy. The approval of the combination of mometasone furoate and formoterol fumarate would further consolidate the company’s respiratory portfolio. Asthma, ...

PennyOmega.com Short Highlights Before the Bell!

PennyOmega.com Hot Stock News & Alerts!

 

Friday August 14, 2009

PennyOmega.com Stocks Upgraded, Downgraded and Short Highlights Before the Bell Friday August 14, 2009

**************************************************************

Schering-Plough Corp (NYSE: SGP) said on Friday that U.S. regulators had approved its Saphris antipsychotic drug, adding a potential blockbuster product as the company is soon to be bought by Merck & Co (NYSE: MRK)

Boeing Co. (NYSE: BA) has stopped production at a 787 Dreamliner facility in Italy that was making parts of the plane’s fuselage. The Chicago-based manufacturer ordered its subcontractor, Alenia Aeronautic in Naples, to stop work two months ago after structural flaws were discovered at where the wing and the fuselage meet,

...

For Immediate Release

Chicago, IL – August 13, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Schering-Plough Corp. (SGP), Caraco Pharmaceutical Laboratories Ltd. (CPD), Dr. Reddy's Laboratories Inc. (RDY), GeoPharma Inc. (GORX) and Mylan Pharmaceuticals Inc. (MYL).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

Schering-Plough Settles Lawsuits

Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex.

This signals the end of all pending

...

Today we are featuring top-performing "Flexible" balanced mutual funds, which primarily seek income or total return through investment in stocks, bonds, or cash to any extent.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Flexible Balanced Funds.3 Solid Picks

Franklin Real Return A (FRRAX) seeks to achieve total return that exceeds the rate of inflation over an economic cycle.

The fund generally invests a substantial portion of its assets in inflation-protected securities. It also has the flexibility to invest in other sectors of the market to increase real return (total return less inflation) potential and offer greater diversification.

T. Anthony Coffey has been lead manager at the fund since its inception in November 2004. The fund has an expense ratio of 0.90%.

Berwyn Income (BERIX) was incepted in September

...

Today we are featuring top-performing "Flexible" balanced mutual funds, which primarily seek income or total return and can invest in stocks, bonds, or cash without limitation.

Investors can find such funds by checking out the entire list of the Zacks #1 Rank Flexible Balanced Funds.

3 Fine Samples

Changing Parameters (CPMPX) seeks total return. The fund invests primarily in futures contracts, options on futures contracts, swap contracts, exchange-traded funds ("ETFs") and U.S. Treasury instruments.

The fund is non-diversified. It typically invests in U.S. Treasuries with maturities of any duration, or their derivatives, and the allocation of its investments between equity and fixed income market segments may vary without limitation.

Robert Levenson has been lead manager at the fund since October 2006. The fund has outperformed the total returns of its benchmark index in the last 1-year period.

Gabelli ABC (GABCX) was incepted

...

For Immediate Release

Chicago, IL - May 22, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co. (MRK), Johnson & Johnson (JNJ), Schering-Plough Corp (SGP), The Coca-Cola Company (KO) and Wal-Mart Stores (WMT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

J&J Mounts Remicade Challenge

In a Schedule 14A proxy statement filed on May 20, 2009 Merck & Co. (MRK) disclosed that it had received notification from Johnson & Johnson's (JNJ) Centocor subsidiary of its intention to terminate, through arbitration,

...

In a Schedule 14A proxy statement filed on May 20, 2009 Merck & Co. (MRK) disclosed that it had received notification from Johnson & Johnson's (JNJ) Centocor subsidiary of its intention to terminate, through arbitration, the distribution agreement with Schering-Plough Corp (SGP) for Remicade and golimumab (Simponi). As we detailed in prior reports and blogs, we had expected some sort of challenge from J&J, so the recent news comes as no surprise.In March 2009 Merck and Co. and Schering-Plough announced a merger agreement whereby the companies would combine in a deal currently valued at approximately $48.8 billion. The deal was structured as a "reverse-merger" with Schering-Plough being the surviving entity. Merck believes that the "reverse-merger" structure will avoid triggering a change-of-control provision in Schering-Plough's agreement with J&J relative to rights to Remicade and golimumab.J&J discovered both compounds and licensed ex-U.S. marketing rights ...